, that reionization was a gradual process, the midpoint of which occurred approximately 400 million years after the Big Bang. However, we have not yet observed the changing ionization state of the IGM directly, and theoretical models struggle to explain how the known population of galaxies at this epoch could have produced enough radiation for reionization to occur.
The problem is twofold: large numbers of faint galaxies seem to be required to supply the necessary radiation 4 , but photons must also be able to escape from the galaxies in which they are produced. Stars form out of cool gas, and thus star-forming galaxies are filled with neutral hydrogen. Neutral hydrogen absorbs ionizing photons and therefore, even in a galaxy whose stars produce copious amounts of energetic radiation, the proportion of this radiation that actually escapes from the galaxy (the escape fraction) may be extremely low.
The Lyman continuum radiation from the galaxies that reionized the Universe will never reach our telescopes, because the photons are absorbed by the IGM long before they get to Earth. It is possible to detect ionizing radiation from closer galaxies, those corresponding to an age of the Universe of approximately 1.6 billion to 2 billion years (see refs 5 and 6, for example), but such detections are complicated by the probability of contamination by non-ionizing radiation originating in faint galaxies along the line of sight. In some ways, galaxies in the local Universe offer the best prospect for a detailed understanding of how ionizing radiation escapes from galaxies. Complicating factors are the unknown similarities and differences between local galaxies and the galaxies of the reionization era, and the fact that Earth's atmosphere blocks the ultraviolet wavelengths of this radiation, requiring that observations be made from space.
Izotov et al. focused on the compact dwarf galaxy J0925 + 1403 -deemed likely to produce escaping ionizing radiation on the basis of properties inferred from its optical emission lines. These lines indicate an unusually high ionization state in the gas near the galaxy's star-forming regions, suggesting that the stars may make more ionizing radiation than can be absorbed by the surrounding gas. The authors' successful detection of ionizing photons is the fourth such observation from a nearby galaxy [7] [8] [9] . Crucially, this galaxy has the highest escape fraction yet measured locally: about 8%, compared with the roughly 1-3% escape fraction measured from other nearby galaxies [7] [8] [9] . The total amount of escaped radiation is sufficient to ionize a mass of IGM gas 40 times greater than the galaxy's stellar mass. Finding Lyman continuum radiation from this galaxy therefore broadly confirms our understanding of the general conditions that may facilitate the escape of ionizing radiation.
However, much work remains to be done to understand how galaxies reionized the Universe: the current study involves a single galaxy, whereas reionization depends on the properties of a population. It is not yet clear whether or not J0925 + 1403 is typical of compact, highly ionized starbursts (galaxies with extremely high rates of star formation) in the nearby Universe. We also do not know whether this galaxy is similar to those that reionized the Universe; its small size, high ionization state and relatively low degree of enrichment by elements heavier than helium generally match the expected properties of such objects, but none of these properties has been measured for the earliest galaxies.
Izotov et al. report that J0925 + 1403 leaks a large number of ionizing photons relative to its ultraviolet luminosity. This finding will inform future theoretical models of the reionization of the Universe by faint galaxies, but it remains to be determined whether this result is typical in the local Universe or representative of galaxies in the reionization era. The authors' detection therefore emphasizes the need for additional, larger studies to develop a statistical understanding of Lyman continuum escape in the local Universe and its relationship to the properties of galaxies more generally. ■
VASCULAR BIOLOGY

Transcriptional control of endothelial energy
The formation of blood vessels requires rapid proliferation of endothelial cells. The transcription factors FOXO1 and MYC have been found to regulate the metabolism and proliferation of vascular endothelial cells. See Letter p.216
C H R I ST E R B E TS H O LT Z
R esearch during the past decade has yielded extensive knowledge of the cellular and molecular mechanisms of angiogenesis, the process through which new blood vessels form from existing ones. Although we have learnt much about how vessels sprout, elongate, branch, form lumens and regress 1 , one piece of the angiogenic puzzle has remained poorly explored: how the proliferation of the endothelial cells that line the vessels' interior is regulated. In this issue, Wilhelm et al. 2 (page 216) show that the transcription factor FOXO1 couples growth-factor signalling to the metabolism, growth and division of endothelial cells. The authors also identify the protein MYC, a known driver of cancer development and the anabolic metabolism that constructs tissues 3 , as a key mediator of endothelial FOXO1 function.
Unicellular organisms have evolved to grow and divide whenever nutrients are abundant, and, conversely, to enter states of inactivity when nutrients are scarce. Multicellular organisms function differently. In our bodies, most cells are exposed to a constant, rich supply of nutrients, but proliferate only when stimulated by growth factors, such as during organ development and regeneration. For endothelial cells, the situation differs again -these cells proliferate and form new blood vessels when oxygen and nutrients are low, with the aim of increasing oxygen and nutrient delivery to other cells in the tissues. Once functional vessels have been established, the endothelial cells, now also exposed to high levels of oxygen and nutrients, cease to proliferate.
Signalling induced when vascular endothelial growth factor A (VEGFA) binds to VEGF receptor 2 (VEGFR2) is the principal driver of most of the fundamental morpho genetic events involved in angiogenesis, including endothelial cell proliferation. A key pathway downstream of VEGFR2 is the PI3K-AKT pathway 4 -a powerful regulator of glucose metabolism and protein synthesis 5 . The protein AKT also inhibits the activity of FOXO transcription factors by phosphorylating them: this causes them to be redistributed from the cell nucleus to the cytoplasm 6 ( Fig. 1) . Wilhelm et al. set out to test the idea that FOXO1, the FOXO family member enriched in endothelial cells, might constitute a link between growth-factor signalling input, metabolism and cell proliferation (Fig. 1) . The researchers inactivated the Foxo1 gene specifically in endothelial cells of newborn mice and found that this led to overgrowth of these cells and the formation of a hugely disorganized and dilated vascular network in the developing mouse retina. Conversely, endothelialspecific expression of a constitutively active FOXO1 protein resulted in a sparse retinal vasculature composed of fewer than normal endothelial cells.
Expression of constitutively active FOXO1 also led to decreased glucose uptake, glycolysis and lactate production in endothelial cells. The authors further observed decreases in oxygen consumption, the production of reactive oxygen species and levels of the energy-carrying molecule ATP -all features that correspond with reduced cellular metabolic activity. The cells survived, but entered a state of metabolic quiescence (a form of dormancy), accompanied by lower expression of genes that are targeted by the transcription factor MYC.
Because MYC is known to regulate all of the above-mentioned metabolic processes, and because inhibition of MYC by FOXO occurs in other cells 6 , the authors tested whether MYC might be the mediator of the proliferation-stimulating effect of Foxo1 inactivation. They found that constitutively active FOXO1 suppressed MYC expression and inactivation of Foxo1 had the opposite effect. FOXO1 also increased expression of negative regulators of MYC activity, including MXI1 and FBXW7, suggesting that FOXO1 inhibits MYC at several levels. Furthermore, the authors show that MYC overexpression restored metabolism and proliferation in endothelial cells with constitutively active FOXO, and repaired vascular defects induced by this treatment. Together, these data provide compelling evidence for MYC as an effector of Foxo1 deficiency in endothelial cells.
Wilhelm and colleagues' work reveals a central mechanism whereby the control of endothelial-cell proliferation is linked to the cells' metabolic state. But as with all good studies, it generates many questions. Does the amount of FOXO1 change during angiogenesis, or is its activity regulated solely by transport in and out of the nucleus, as the authors' results might suggest (see Figure 1a of the paper 2 )? Although the experimental methods used by the authors are the best available, they involved vast changes in FOXO1 levels (complete loss or several-fold increase), which would not occur in physiological settings. The striking normalization of the retinal vasculature observed in mice overexpressing both constitutively active FOXO1 and MYC might result from a new balance, achieved through similarly increased levels of the two. A more critical test of the role of FOXO1 as a 'rheostat' of vascular expansion, a term used by the authors, should ideally include manipulations of the activity of FOXO1 -such as of its nuclear-cytoplasmic shuttling -at normal levels.
Moreover, the question of how FOXO1 nuclear translocation is regulated in endothelial cells remains unresolved. In analogy with the regulation of other FOXO proteins by a growthfactor-PI3K-AKT axis, one would guess that signalling downstream of VEGFA-VEGFR2 binding plays a central part. However, FOXOs have several upstream inputs besides AKT 6 , and FOXO1 signalling and its role in endothelial cells might be multifaceted and contextdependent. For example, in adult mice, deletion of multiple FOXO proteins, including FOXO1, leads to the formation of benign endothelialcell tumours known as haemangiomas in some organs, but not all 7 . Similarly, VEGF induces enhanced proliferation in cultures of non-FOXO-expressing endothelial cells from some organs, but not others 7 .
Although this association between FOXO dysregulation and endothelial tumour formation concurs with Wilhelm and colleagues' idea that FOXO1 is a major regulator of endothelial-cell proliferation, and extend their observations into adult animals, the nonuniform and tissue-type-dependent responses are intriguing. 2 show that, in these endothelial cells, the transcription factor FOXO1 is located in the cytoplasm, possibly as a result of having been phosphorylated (P) through the activity of the PI3K-AKT signalling pathway that is induced when vascular endothelial growth factor A (VEGFA) binds to its receptor (VEGFR2). As a consequence, FOXO1 cannot exert its function, described by the authors, in inhibiting the transcription factor MYC, which remains in the nucleus. The resulting enhanced MYC activity leads to increased cellular metabolism, growth and proliferation. By contrast, vessel maturation, which occurs more centrally in the vascular network, coincides with cessation of growth-factor signalling. Presumably at this stage, FOXO1, now non-phosphorylated, moves to the nucleus and inhibits MYC, thereby inducing endothelial-cell quiescence.
